Sign In
Buy IRWD
$3.24
-0.0400 (-1.22%)
At Close: Jun 03, 2026
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
11:41am, Friday, 08'th Aug 2025
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
09:26am, Thursday, 07'th Aug 2025
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
07:05am, Thursday, 07'th Aug 2025
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
12:37pm, Friday, 06'th Jun 2025
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
10:55am, Thursday, 08'th May 2025
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
09:20am, Wednesday, 07'th May 2025
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
07:05am, Wednesday, 07'th May 2025
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 01'st May 2025
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
04:25pm, Wednesday, 30'th Apr 2025
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7t
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
07:05am, Friday, 25'th Apr 2025
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and r
Ironwood Shares Tank on Regulatory Update for Apraglutide
10:20am, Tuesday, 15'th Apr 2025
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
02:19pm, Monday, 14'th Apr 2025
Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intes
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
07:00am, Monday, 14'th Apr 2025
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
10:49am, Thursday, 10'th Apr 2025
Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZE
